Palatin Technologies, Inc. (PTNT)

Market Cap	7.98M
Revenue (ttm)	n/a
Net Income (ttm)	-17.31M
Shares Out	n/a
EPS (ttm)	-32.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	751
Average Volume	3,150
Open	5.75
Previous Close	5.75
Day's Range	5.75 - 5.95
52-Week Range	1.75 - 72.50
Beta	n/a
RSI	33.72
Earnings Date	Sep 30, 2025

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company als...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 29
• Stock Exchange: OTCMKTS
• Ticker Symbol: PTNT